메뉴 건너뛰기




Volumn 15, Issue 2, 2017, Pages 229-239.e5

Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists

Author keywords

Biologic Naive; GEMINI; Inflammatory Bowel Disease; Treatment Failure

Indexed keywords

PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY; VEDOLIZUMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

EID: 85009431279     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.08.044     Document Type: Article
Times cited : (169)

References (38)
  • 1
    • 80455140368 scopus 로고    scopus 로고
    • Ulcerative colitis
    • 1 Danese, S., Fiocchi, C., Ulcerative colitis. N Engl J Med 365 (2011), 1713–1725.
    • (2011) N Engl J Med , vol.365 , pp. 1713-1725
    • Danese, S.1    Fiocchi, C.2
  • 2
    • 28844473957 scopus 로고    scopus 로고
    • Infliximab for induction and maintenance therapy for ulcerative colitis
    • 2 Rutgeerts, P., Sandborn, W.J., Feagan, B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005), 2462–2476.
    • (2005) N Engl J Med , vol.353 , pp. 2462-2476
    • Rutgeerts, P.1    Sandborn, W.J.2    Feagan, B.G.3
  • 3
    • 84856163835 scopus 로고    scopus 로고
    • Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis
    • 3 Sandborn, W.J., van Assche, G., Reinisch, W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142 (2012), 257–265.
    • (2012) Gastroenterology , vol.142 , pp. 257-265
    • Sandborn, W.J.1    van Assche, G.2    Reinisch, W.3
  • 4
    • 84890620601 scopus 로고    scopus 로고
    • Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis
    • 4 Sandborn, W.J., Feagan, B.G., Marano, C., et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 85–95.
    • (2014) Gastroenterology , vol.146 , pp. 85-95
    • Sandborn, W.J.1    Feagan, B.G.2    Marano, C.3
  • 5
    • 84890629055 scopus 로고    scopus 로고
    • Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis
    • 5 Sandborn, W.J., Feagan, B.G., Marano, C., et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 96–109.
    • (2014) Gastroenterology , vol.146 , pp. 96-109
    • Sandborn, W.J.1    Feagan, B.G.2    Marano, C.3
  • 6
    • 84881187537 scopus 로고    scopus 로고
    • Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials
    • 6 Ford, A.C., Peyrin-Biroulet, L., Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 108 (2013), 1268–1276.
    • (2013) Am J Gastroenterol , vol.108 , pp. 1268-1276
    • Ford, A.C.1    Peyrin-Biroulet, L.2
  • 7
    • 84863724798 scopus 로고    scopus 로고
    • A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease
    • 7 Lichtenstein, G.R., Rutgeerts, P., Sandborn, W.J., et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 107 (2012), 1051–1063.
    • (2012) Am J Gastroenterol , vol.107 , pp. 1051-1063
    • Lichtenstein, G.R.1    Rutgeerts, P.2    Sandborn, W.J.3
  • 8
    • 70349086185 scopus 로고    scopus 로고
    • The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases
    • 8 Soler, D., Chapman, T., Yang, L.L., et al. The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 330 (2009), 864–875.
    • (2009) J Pharmacol Exp Ther , vol.330 , pp. 864-875
    • Soler, D.1    Chapman, T.2    Yang, L.L.3
  • 9
    • 84929773619 scopus 로고    scopus 로고
    • Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab
    • 9 Wyant, T., Estevam, J., Yang, L., et al. Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab. Cytometry B Clin Cytom 90 (2016), 168–176.
    • (2016) Cytometry B Clin Cytom , vol.90 , pp. 168-176
    • Wyant, T.1    Estevam, J.2    Yang, L.3
  • 10
    • 84867576762 scopus 로고    scopus 로고
    • Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates
    • 10 Fedyk, E.R., Wyant, T., Yang, L.L., et al. Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis 18 (2012), 2107–2119.
    • (2012) Inflamm Bowel Dis , vol.18 , pp. 2107-2119
    • Fedyk, E.R.1    Wyant, T.2    Yang, L.L.3
  • 11
    • 84874280106 scopus 로고    scopus 로고
    • Antagonizing the α4β7 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis
    • 11 Haanstra, K.G., Hofman, S.O., Lopes Estevao, D.M., et al. Antagonizing the α4β7 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J Immunol 190 (2013), 1961–1973.
    • (2013) J Immunol , vol.190 , pp. 1961-1973
    • Haanstra, K.G.1    Hofman, S.O.2    Lopes Estevao, D.M.3
  • 12
    • 0029826678 scopus 로고    scopus 로고
    • Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin α4β7
    • 12 Hesterberg, P.E., Winsor-Hines, D., Briskin, M.J., et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin α4β7. Gastroenterology 111 (1996), 1373–1380.
    • (1996) Gastroenterology , vol.111 , pp. 1373-1380
    • Hesterberg, P.E.1    Winsor-Hines, D.2    Briskin, M.J.3
  • 13
    • 84886788747 scopus 로고    scopus 로고
    • Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype
    • 13 Milch, C., Wyant, T., Xu, J., et al. Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol 264 (2013), 123–126.
    • (2013) J Neuroimmunol , vol.264 , pp. 123-126
    • Milch, C.1    Wyant, T.2    Xu, J.3
  • 14
    • 85009355752 scopus 로고    scopus 로고
    • Entyvio (vedolizumab)
    • [package insert] Takeda Pharmaceuticals America, Inc. Deerfield, IL
    • 14 Takeda, Entyvio (vedolizumab). [package insert], 2014, Takeda Pharmaceuticals America, Inc., Deerfield, IL.
    • (2014)
    • Takeda1
  • 15
    • 84882769357 scopus 로고    scopus 로고
    • Vedolizumab as induction and maintenance therapy for ulcerative colitis
    • 15 Feagan, B.G., Rutgeerts, P., Sands, B.E., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369 (2013), 699–710.
    • (2013) N Engl J Med , vol.369 , pp. 699-710
    • Feagan, B.G.1    Rutgeerts, P.2    Sands, B.E.3
  • 16
    • 69049110950 scopus 로고    scopus 로고
    • Confidence interval or p-value? Part 4 of a series on evaluation of scientific publications
    • 16 du Prel, J.B., Hommel, G., Rohrig, B., et al. Confidence interval or p-value? Part 4 of a series on evaluation of scientific publications. Dtsch Arztebl Int 106 (2009), 335–339.
    • (2009) Dtsch Arztebl Int , vol.106 , pp. 335-339
    • du Prel, J.B.1    Hommel, G.2    Rohrig, B.3
  • 17
    • 0032991290 scopus 로고    scopus 로고
    • The medical dictionary for regulatory activities (MedDRA)
    • 17 Brown, E.G., Wood, L., Wood, S., The medical dictionary for regulatory activities (MedDRA). Drug Saf 20 (1999), 109–117.
    • (1999) Drug Saf , vol.20 , pp. 109-117
    • Brown, E.G.1    Wood, L.2    Wood, S.3
  • 18
    • 84960145681 scopus 로고    scopus 로고
    • The safety of vedolizumab for ulcerative colitis and Crohn's disease
    • [Epub ahead of print]
    • 18 Colombel, J.F., Sands, B.E., Rutgeerts, P., et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut, 2016 [Epub ahead of print].
    • (2016) Gut
    • Colombel, J.F.1    Sands, B.E.2    Rutgeerts, P.3
  • 19
    • 84869456003 scopus 로고    scopus 로고
    • Strategies for the care of adults hospitalized for active ulcerative colitis
    • 19 Pola, S., Patel, D., Ramamoorthy, S., et al. Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol 10 (2012), 1315–1325 e4.
    • (2012) Clin Gastroenterol Hepatol , vol.10 , pp. 1315-1325 e4
    • Pola, S.1    Patel, D.2    Ramamoorthy, S.3
  • 20
    • 34347402306 scopus 로고    scopus 로고
    • Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial
    • 20 Sandborn, W.J., Rutgeerts, P., Enns, R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146 (2007), 829–838.
    • (2007) Ann Intern Med , vol.146 , pp. 829-838
    • Sandborn, W.J.1    Rutgeerts, P.2    Enns, R.3
  • 21
    • 84864714487 scopus 로고    scopus 로고
    • Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease
    • 21 de Silva, P.S., Nguyen, D.D., Sauk, J., et al. Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. Aliment Pharmacol Ther 36 (2012), 459–466.
    • (2012) Aliment Pharmacol Ther , vol.36 , pp. 459-466
    • de Silva, P.S.1    Nguyen, D.D.2    Sauk, J.3
  • 22
    • 84899061007 scopus 로고    scopus 로고
    • Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease
    • 22 Rubin, D.T., Mody, R., Davis, K.L., et al. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther 39 (2014), 1143–1155.
    • (2014) Aliment Pharmacol Ther , vol.39 , pp. 1143-1155
    • Rubin, D.T.1    Mody, R.2    Davis, K.L.3
  • 23
    • 79953788656 scopus 로고    scopus 로고
    • Assessing response and loss of response to biological therapies in IBD
    • 23 Yanai, H., Hanauer, S.B., Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 106 (2011), 685–698.
    • (2011) Am J Gastroenterol , vol.106 , pp. 685-698
    • Yanai, H.1    Hanauer, S.B.2
  • 24
    • 85033597671 scopus 로고    scopus 로고
    • Optimizing the use of biological therapy in patients with inflammatory bowel disease
    • 24 Moss, A.C., Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf) 3 (2015), 63–68.
    • (2015) Gastroenterol Rep (Oxf) , vol.3 , pp. 63-68
    • Moss, A.C.1
  • 25
    • 84855648247 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of biologics for inflammatory bowel disease
    • 25 Colombel, J.F., Feagan, B.G., Sandborn, W.J., et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 18 (2012), 349–358.
    • (2012) Inflamm Bowel Dis , vol.18 , pp. 349-358
    • Colombel, J.F.1    Feagan, B.G.2    Sandborn, W.J.3
  • 26
    • 77951974444 scopus 로고    scopus 로고
    • Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease
    • 26 Afif, W., Loftus, E.V. Jr., Faubion, W.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 105 (2010), 1133–1139.
    • (2010) Am J Gastroenterol , vol.105 , pp. 1133-1139
    • Afif, W.1    Loftus, E.V.2    Faubion, W.A.3
  • 27
    • 84904727989 scopus 로고    scopus 로고
    • Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: additional results from GEMINI 1 and 2 [abstract]
    • 27 Rosario, M., Fox, I., Milch, C., et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: additional results from GEMINI 1 and 2 [abstract]. Inflamm Bowel Dis, 19(Suppl 1), 2013, 140.
    • (2013) Inflamm Bowel Dis , vol.19 , pp. 140
    • Rosario, M.1    Fox, I.2    Milch, C.3
  • 28
    • 77950988234 scopus 로고    scopus 로고
    • Infliximab, azathioprine, or combination therapy for Crohn's disease
    • 28 Colombel, J.F., Sandborn, W.J., Reinisch, W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362 (2010), 1383–1395.
    • (2010) N Engl J Med , vol.362 , pp. 1383-1395
    • Colombel, J.F.1    Sandborn, W.J.2    Reinisch, W.3
  • 29
    • 84899998067 scopus 로고    scopus 로고
    • Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy
    • 29 Subramaniam, K., Richardson, A., Dodd, J., et al. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy. Intern Med J 44 (2014), 464–470.
    • (2014) Intern Med J , vol.44 , pp. 464-470
    • Subramaniam, K.1    Richardson, A.2    Dodd, J.3
  • 30
    • 84881542095 scopus 로고    scopus 로고
    • Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome
    • 30 Garcia-Bosch, O., Gisbert, J.P., Canas-Ventura, A., et al. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis 7 (2013), 717–722.
    • (2013) J Crohns Colitis , vol.7 , pp. 717-722
    • Garcia-Bosch, O.1    Gisbert, J.P.2    Canas-Ventura, A.3
  • 31
    • 84900550345 scopus 로고    scopus 로고
    • Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis
    • 31 Hayes, M.J., Stein, A.C., Sakuraba, A., Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis. J Gastroenterol Hepatol 29 (2014), 1177–1185.
    • (2014) J Gastroenterol Hepatol , vol.29 , pp. 1177-1185
    • Hayes, M.J.1    Stein, A.C.2    Sakuraba, A.3
  • 32
    • 84892737455 scopus 로고    scopus 로고
    • Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis
    • 32 Panaccione, R., Ghosh, S., Middleton, S., et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146 (2014), 392–400 e3.
    • (2014) Gastroenterology , vol.146 , pp. 392-400 e3
    • Panaccione, R.1    Ghosh, S.2    Middleton, S.3
  • 33
    • 84929908673 scopus 로고    scopus 로고
    • Which patients with inflammatory bowel disease should receive combination therapy?
    • 33 Cross, R.K., Which patients with inflammatory bowel disease should receive combination therapy?. Expert Rev Gastroenterol Hepatol 9 (2015), 715–717.
    • (2015) Expert Rev Gastroenterol Hepatol , vol.9 , pp. 715-717
    • Cross, R.K.1
  • 34
    • 84887210548 scopus 로고    scopus 로고
    • Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease
    • 34 Orlando, A., Guglielmi, F.W., Cottone, M., et al. Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease. Dig Liver Dis 45 (2013), 986–991.
    • (2013) Dig Liver Dis , vol.45 , pp. 986-991
    • Orlando, A.1    Guglielmi, F.W.2    Cottone, M.3
  • 35
    • 84930015437 scopus 로고    scopus 로고
    • Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease
    • 35 Vande Casteele, N., Ferrante, M., Van Assche, G., et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 148 (2015), 1320–1329.
    • (2015) Gastroenterology , vol.148 , pp. 1320-1329
    • Vande Casteele, N.1    Ferrante, M.2    Van Assche, G.3
  • 36
    • 84894640694 scopus 로고    scopus 로고
    • Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives
    • 36 Vande Casteele, N., Feagan, B.G., Gils, A., et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep, 16, 2014, 378.
    • (2014) Curr Gastroenterol Rep , vol.16 , pp. 378
    • Vande Casteele, N.1    Feagan, B.G.2    Gils, A.3
  • 37
    • 79751472562 scopus 로고    scopus 로고
    • The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
    • quiz 3
    • 37 D'Haens, G.R., Panaccione, R., Higgins, P.D., et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. Am J Gastroenterol 106 (2011), 199–212 quiz 3.
    • (2011) Am J Gastroenterol , vol.106 , pp. 199-212
    • D'Haens, G.R.1    Panaccione, R.2    Higgins, P.D.3
  • 38
    • 84886946831 scopus 로고    scopus 로고
    • Optimizing anti-TNF treatments in inflammatory bowel disease
    • 38 Ben-Horin, S., Kopylov, U., Chowers, Y., Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 13 (2014), 24–30.
    • (2014) Autoimmun Rev , vol.13 , pp. 24-30
    • Ben-Horin, S.1    Kopylov, U.2    Chowers, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.